Ege Tıp Dergisi
Development of an extracellular vesicle-based shRNA delivery system to overcome cisplatin resistance in non-small cell lung cancer by targeting STAT3
Aim: Cisplatin resistance remains a major clinical challenge in non-small cell lung cancer, frequently driven by STAT3 activation. This study aimed to engineer an autologous extracellular vesicle (EV) formulation loaded with anti-STAT3 shRNA-encoding plasmid DNA to resensitize cisplatin-resistant Calu1 lung cancer cells.Materials and Methods: EVs were isolated from parental Calu1 cell culture supernatants via modified differential ultracentrifugation and characterized using electron microscopy, atomic force microsc …